D. Osborne
Director of Finance/CFO presso Melt Pharmaceuticals, Inc.
Profilo
D.
Bradford Osborne is currently the Chief Financial Officer at Melt Pharmaceuticals, Inc. Prior to this, he worked at Precigen, Inc. as the Principal Accounting Officer & VP-Finance from 2011 to 2021.
Posizioni attive di D. Osborne
| Società | Posizione | Inizio |
|---|---|---|
Melt Pharmaceuticals, Inc.
 Melt Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Melt Pharmaceuticals, Inc. engages in the development and commercialization of proprietary non-opioid, non-intravenous, or non-IV, sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. It intends to seek regulatory approval through the FDA regulatory pathway for the proprietary, patented small-molecule product candidates. The company was founded by Mark L. Baum on April 3, 2018 and is headquartered in Brentwood, TN. | Director of Finance/CFO | 01/02/2022 |
Precedenti posizioni note di D. Osborne
| Società | Posizione | Fine |
|---|---|---|
| PRECIGEN, INC. | Director of Finance/CFO | 10/06/2021 |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| PRECIGEN, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Melt Pharmaceuticals, Inc.
Melt Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Melt Pharmaceuticals, Inc. engages in the development and commercialization of proprietary non-opioid, non-intravenous, or non-IV, sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. It intends to seek regulatory approval through the FDA regulatory pathway for the proprietary, patented small-molecule product candidates. The company was founded by Mark L. Baum on April 3, 2018 and is headquartered in Brentwood, TN. | Health Technology |
- Borsa valori
- Insiders
- D. Osborne
